SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 13, 2004
DRAGON PHARMACEUTICAL INC.
(Exact Name of Registrant as Specified in Charter)
Florida 0-27937 65-0142474
------------------------------- ------------------------ ---------------------
(State or Other Jurisdiction of (Commission File Number) (IRS Employer
Incorporation) Identification No.)
1055 Hastings Street, Suite 1900
Vancouver, British Columbia V6E 2E9
--------------------------------------- ---------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (604) 669-8817
N/A
(Former Name or Former Address, if Changed Since Last Report)
Item 7. Financial Statements and Exhibits
(c) Exhibits
99.1 Press release dated May 13, 2004
Item 12. Results of Operations and Financial Condition
The purpose of this current report on Form 8-K is to disclose that Dragon
Pharmaceutical Inc. issued a press release on May 13, 2004 announcing and
summarizing its financial results for the three-month period ending March 31,
2004.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DRAGON PHARMACEUTICAL INC.
Date: May 14, 2004 By: /s/ Matthew Kavanagh
------------------------------------
Name: Matthew Kavanagh
Title: Director of Finance and Compliance
(Principal Financial and Accounting
Officer)